Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058279 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00058279: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00058279 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00058279, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining monoclonal antibody therapy with interleukin-2 may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining monoclonal antibody therapy with interleukin-2 in treating patients who have metastatic melanoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL ipilimumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-02 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058279
The ClinicalTrials.gov registry entry for NCT00058279 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00058279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058279 about?
NCT00058279 is a clinical study titled "Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma". RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining monoclonal antibody therapy with interleukin-2 may kill more tumor cells....
What is the current status of trial NCT00058279?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-02. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00058279?
The interventions under investigation include: aldesleukin (BIOLOGICAL), ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00058279?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.